Biopsy Devices Market Size to Exceed USD 2399 Million by 2022

first_imgBiopsy Devices Market was valued at $1,621 million, and is expected to reach $2,399 million by 2022, supported by a CAGR of 5.8%. Biopsy is the surgical removal of tissue from an organ to determine the presence or extent of a disease, mostly cancerous and inflammatory conditions. Increasing incidences of cancer such as breast, prostate, & lung, and rapid technological advancements have been stimulating the growth of the biopsy devices market.Breast biopsy application segment is expected to continue to lead the market because of increased incidences and mortality rates of breast cancer. Moreover, initiatives by various government bodies to spread awareness about breast cancer is expected to supplement the growth of the breast biopsy devices market. A breast biopsy is followed by liver & bile duct biopsy, which is the second-highest revenue-generating application segment globally.Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/1424Biopsy devices market is owing to increase in several types of cancer such, as breast, prostate, & lung, and rapid technological advancements in the field of diagnostics. The emerging economies have witnessed an upsurge in the prevalence of chronic diseases due to increasing in the aged population and change in lifestyles. The Emergence of novel biopsy techniques and advanced integrated imaging technology, such as MRI, CT, ultrasound scan, and others, are expected to supplement the diagnosis of chronic diseases namely, cancer using biopsy procedures. However, high cost associated with advanced biopsy technologies may restrict market growth.Key Findings of Biopsy Devices Market:• CT-guided biopsy segment is anticipated to grow at the highest CAGR of 6.3% during the forecast period.• The diagnostic centers would continue to lead the revenue generating end use segment by garnering around half of the share in the overall market.• Lung biopsy is projected to be the fastest growing application segment, registering a CAGR of 7.0%.• The robotic guidance system segment is expected to register the highest CAGR of 7.0%.• The Asia-Pacific region is projected to be the fastest-growing market, with a CAGR of 7.2%.• Hospitals are projected to be the fastest-growing end-use segment, owing to the increase in integration of diagnostic facilities within the premises.North America was the highest revenue-generating region due to the rise in incidences of chronic diseases in 2015. North America and Europe, collectively, accounted for more than three-fourths of the overall market in 2015; this trend is likely to continue over the forecast period. Factors that drive the growth of biopsy devices in the developed regions are awareness about cancer diagnosis, high purchasing power, and availability of skilled personnel to perform biopsy procedures.The key companies profiled in the report are C.R. Bard, Inc., Leica Biosystems, Hologic, Inc., Becton, Dickinson and Company, Ethicon EndoSurgery Inc., Fujifilm Medical Systems, Veran Medical Technologies, Boston Scientific Corporation, MDxHealth, Mauna Kea Technologies, Cook Medical, Inc., Medtronic, Argon Medical Devices, Inc, Intact Medical Corp., and others.Get More Details @ https://www.alliedmarketresearch.com/purchase-enquiry/1424Table Of ContentChapter: 1 INTRODUCTION1.1 Report description1.2 Key benefits1.3 Key market segments1.4 Research methodology1.4.1 Secondary research1.4.2 Primary research1.4.3 Analyst tools and modelsChapter: 2 EXECUTIVE SUMMARY2.1 CXO perspective2.2 Market beyond: what to expect by 20252.2.1 Moderate growth scenario2.2.2 Rapid growth scenario2.2.3 Diminishing growth scenarioChapter: 3 BIOPSY DEVICE MARKET OVERVIEW3.1 Market definition and scope3.2 Market Dynamics3.2.1 Top impacting factors3.2.2 Drivers3.2.3 Restrains3.2.4 Top winning strategies3.3 Porters Five Forces analysis3.3.1 Fewer suppliers lead to higher bargaining power of suppliers3.3.2 Higher concentration of buyers leads to low bargaining power3.3.3 High threat of substitutes due to presence of minimal invasive diagnostic procedures3.3.4 Low threat of new entrants due to high capital investment3.3.5 Moderate competitive rivalry3.4 Value chain analysis3.4.1 Research and product development3.4.2 Product testing3.4.3 Manufacturing3.4.4 End users3.5 Regulatory norms3.5.1 Regulatory issues of gastroenterology and urology biopsy devices in North America3.5.2 Regulatory Scenario for breast biopsy in European Union3.6 Reimbursement scenario3.6.1 Reimbursement for Breast Cancer Screening in the U.S.3.6.2 Reimbursement for Breast Reconstruction or Prosthesis3.7 Patent analysis3.7.1 The U.S.: Patent analysis, by market participants3.7.2 Europe: Patent analysis, by market participant3.7.3 Japan: Patent analysis, by market participantsAccess Full Summary @ https://www.alliedmarketresearch.com/press-release/biopsy-devices-market.html Biopsy Devices Marketlast_img

Leave a Reply

Your email address will not be published. Required fields are marked *